艾塞那肽联合川芎嗪治疗糖尿病视网膜病变临床观察

发布时间：2018-10-24 20:46

【摘要】：目的观察艾塞那肽联合川芎嗪对糖尿病视网膜病变(DR)患者球后动脉血流动力学变化情况及临床疗效。方法选择2014年2月—2015年8月收治的DR 80例,按治疗方法分为观察组和对照组,每组40例。两组均给予艾塞那肽+二甲双胍+羟苯磺酸钙胶囊,观察组在此基础上给予磷酸川芎嗪片,治疗30 d。观察两组空腹血糖(FPG)、餐后2 h血糖(2 h PBG)及视网膜中央动脉(CRA)、睫状后动脉(PCA)、眼动脉(OA)收缩期最高血流速度(PSV)、舒张末期最低血流速度(EDV)、阻力指数(RI)的变化情况,记录治疗过程中的不良反应并评估临床疗效。结果两组治疗后Hb A1c、FPG、2 h PBG均较治疗前降低(P0.05),但两组间比较差异无统计学意义(P0.05)。治疗后两组CRA、PCA、OA PSV及EDV均高于治疗前,RI低于治疗前(P0.01);治疗后观察组CRA、PCA、OA PSV及EDV均高于对照组,RI低于对照组(P0.05)。观察组临床疗效优于对照组(P0.05)。两组均未发生严重不良反应,且发生率比较差异无统计学意义(P0.05)。结论艾塞那肽联合川芎嗪治疗DR能有效改善球后动脉血流,提高临床疗效,安全性高。
[Abstract]:Objective to observe the hemodynamic changes of retrobulbar artery in patients with diabetic retinopathy (DR) treated with isenapeptide combined with ligustrazine. Methods from February 2014 to August 2015, 80 patients with DR were divided into observation group and control group with 40 cases in each group. Both groups were given calcium capsules of isenapeptide metformin hydroxylbenzenesulfonate and the observation group were treated with ligustrazine phosphate tablets for 30 days. The changes of fasting blood glucose (FPG),) 2 h postprandial blood glucose (2 h PBG) and (PCA), posterior ciliary artery (PCA),) (OA) systolic maximum blood flow velocity (PSV),) at end diastolic end of (EDV), resistance index (RI) were observed in both groups. Record adverse reactions during treatment and evaluate clinical efficacy. Results the 2 h PBG of Hb A1cFG in the two groups was lower than that before treatment (P0.05), but there was no significant difference between the two groups (P0.05). After treatment, CRA,PCA,OA PSV and EDV in both groups were higher than those before treatment, RI was lower than that before treatment (P0.01), CRA,PCA,OA PSV and EDV in observation group were higher than those in control group, RI was lower than that in control group (P0.05). The clinical effect of the observation group was better than that of the control group (P0.05). There was no serious adverse reaction between the two groups, and there was no significant difference in the incidence rate (P0.05). Conclusion the combination of isenapeptide and ligustrazine can effectively improve the blood flow of retrobulbar artery and improve the clinical efficacy and safety of DR.
【作者单位】：沈阳医学院附属中心医院内分泌科;
【基金】：沈阳市科技计划项目基金(F13-220-9-10)
【分类号】：R587.2;R774.1

【相似文献】